Literature DB >> 30243738

The effects of Kasai procedure on living donor liver transplantation for children with biliary atresia.

Shanni Li1, Nan Ma1, Xingchu Meng1, Wei Zhang1, Chao Sun1, Chong Dong1, Kai Wang1, Bin Wu1, Wei Gao2.   

Abstract

OBJECTIVE: To evaluate the effects of Kasai procedure (hepatic portoenterostomy) on living donor liver transplantation (LDLT) for children with biliary atresia (BA).
METHODS: From January 2006 to January 2014, 150 children with BA were treated with LDLT in China. The children were categorized into pre-Kasai and non-Kasai groups, based on whether they had previously undergone Kasai procedure. Clinical data were retrospectively analyzed, and the difference in postoperative survival was compared between the groups. Preoperative data, including height, weight, serum bilirubin, and pediatric end-stage liver disease score, and perioperative blood loss, operation duration, incidence of postoperative surgical complications including vascular complications, bile duct complications, lymphatic fluid leakage, and digestive tract fistula were compared between the groups.
RESULTS: In total, 89 and 61 children were categorized in the pre-Kasai and non-Kasai groups, respectively. The 1-, 6-, and 12-month survival was 97.8%, 95.4%, and 95.4% for the Kasai group, and 98.4%, 96.7%, and 96.7% for the non-Kasai group, respectively (P > 0.05). The differences in mean operation duration and mean blood loss, and the incidences of outflow tract obstruction, portal vein stenosis, hepatic artery thrombosis, bile duct complications, lymphatic fluid leakage, and digestive tract fistula were not statistically significant between the groups (P > 0.05).
CONCLUSION: Kasai procedure could effectively delay the requirement of liver transplantation. In light of previous findings that Kasai procedure could significantly improve the liver transplantation-free survival of children with BA, we suggest that Kasai procedure should be used as a first-line treatment method for this condition. TYPE OF STUDY: Treatment Study. LEVEL OF EVIDENCE: Level III.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliary atresia; Children; Kasai procedure; Liver transplantation; Living donor

Mesh:

Year:  2018        PMID: 30243738     DOI: 10.1016/j.jpedsurg.2018.07.022

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  5 in total

1.  Pediatric living donor liver transplantation (LDLT): Short- and long-term outcomes during sixteen years period at a single centre- A retrospective cohort study.

Authors:  Emad Hamdy Gad; Ahmed Nabil Sallam; Hosam Soliman; Tarek Ibrahim; Tahany Abdel Hameed Salem; Mohammed Abdel-Hafez Ali; Mohammed Al-Sayed Abd-Same; Islam Ayoub
Journal:  Ann Med Surg (Lond)       Date:  2022-06-07

Review 2.  Biliary Atresia: A Complex Hepatobiliary Disease with Variable Gene Involvement, Diagnostic Procedures, and Prognosis.

Authors:  Consolato M Sergi; Susan Gilmour
Journal:  Diagnostics (Basel)       Date:  2022-01-27

3.  Liver stiffness measurement predicts the difficulty of Kasai procedure in biliary atresia: a single center retrospective analysis of 199 patients.

Authors:  Qiulong Shen; Yajun Chen; Chunhui Peng; Wenbo Pang; Zengmeng Wang; Dongyang Wu; Kai Wang; Xinjie Huang
Journal:  BMC Pediatr       Date:  2019-11-29       Impact factor: 2.125

4.  Characteristics of Gut Microbiota in Children With Biliary Atresia After Liver Transplantation.

Authors:  Wei Song; Li-Ying Sun; Zhi-Jun Zhu; Lin Wei; Wei Qu; Zhi-Gui Zeng; Yun-Sheng Yang
Journal:  Front Physiol       Date:  2021-06-29       Impact factor: 4.566

5.  Sequential Treatment of Biliary Atresia With Kasai Hepatoportoenterostomy and Liver Transplantation: Benefits, Risks, and Outcome in 393 Children.

Authors:  Roberto Tambucci; Catherine de Magnée; Margot Szabo; Aniss Channaoui; Aurore Pire; Vanessa de Meester de Betzenbroeck; Isabelle Scheers; Xavier Stephenne; Françoise Smets; Etienne M Sokal; Raymond Reding
Journal:  Front Pediatr       Date:  2021-07-07       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.